EA4231: ViPOR in r/r DLBCL and HGBCL-DH-BCL2

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
Protocol EA4231, A Phase II Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed or Refractory CD10-Negative Diffuse-Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma with MYC and BCL2 rearrangements (HGBCL-DH-BCL2),(NCT 06649812)
Principal Investigator
Headshot of Disha Dalela
Assistant Professor of Medicine
Protocol Number
IRB: PRO00119831
NCT: NCT06649812
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL